Pharmacy Times reports Tauklarify (florquinitau F 18 injection) is a tau PET tracer that shows tangle pathology in impaired adults evaluated for Alzheimer's disease. FDA materials indicate blood tests offer less-invasive amyloid triage, while tau PET maps tangle burden with added precautions. Tau tangles are twisted fibers inside brain cells that disrupt memory circuits. Amyloid plaques are protein clumps between cells that often appear earlier and help confirm Alzheimer's biology.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test measure?
- How accurate is tau PET?
- Where do blood tests fit in primary care?
- What should you discuss before testing?
What does each test measure?
Pharmacy Times reports FDA approved Tauklarify for tau PET in cognitively impaired adults evaluated for Alzheimer's disease to detect tangle pathology Pharmacy Times approval report. The scan highlights where tau has spread across memory areas. The U.S. FDA states it cleared Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio on May 16, 2025 to aid early detection of amyloid plaques FDA clearance announcement.
The clearance covers adults age 55 and older with signs and symptoms. Medical News Today reports FDA cleared Roche and Eli Lilly's Elecsys Phospho-Tau 217P plasma test on Aug. 24, 2026 as a single-biomarker blood test Medical News Today report. It helps physicians detect Alzheimer's signs without requiring an amyloid ratio calculation.
How accurate is tau PET?
Pharmacy Times describes two studies with five blinded readers scoring scans. Positive agreement ran 68%-88% and negative agreement ran 93%-99%, with strong interreader reliability.
Headache occurred in 0.7% of 1,734 exposed participants. Pharmacy Times notes labeling warns of misdiagnosis because testing focused on amyloid-PET-negative unimpaired versus amyloid-positive impaired patients. A negative scan does not exclude tau pathology, and a positive scan does not prove histologic disease.
Where do blood tests fit in primary care?
FDA information presents blood tests as less-invasive, more accessible amyloid triage that reduces reliance on PET or spinal fluid. That makes them a practical first step when memory concerns arise in primary care.
Discover Pharma, reporting the Alzheimer's Association, says the first blood-biomarker guideline was announced at AAIC 2025 and published in Alzheimer's & Dementia. It endorses brand-agnostic blood tests meeting sensitivity and specificity thresholds for cognitively impaired patients in specialty care.
What should you discuss before testing?
Ask whether symptoms, age, and exam findings match the cleared uses for blood testing or tau PET. Bring a full medication list and note kidney issues, pregnancy status, and prior reactions to tracers.
FDA information ties PET safety steps to hydration, frequent voiding, and medication review. Schedule time to review results with your clinician rather than judging a positive or negative alone.
- Blood draw first for amyloid triage when access or comfort matters
- Tau PET when the doctor needs tangle location after impairment workup
- Review medications, hydration, voiding and radiation precautions before PET
